• Focus on innovation and opportunity for companies and investors
• Key conference for life science and investing in the region with more than 200 international attendees

Montreal, September 19, 2017

TVM Capital Life Science convened its 6^th annual Autumn Conference in Montreal yesterday, with more than 200 international attendees from Asia, the United States, Europe and Canada who networked with senior decision makers from biotech and pharmaceutical companies as well as venture capital groups. The overall theme of the conference focused on how to best stimulate innovation for the pharmaceutical industry, the investment opportunities in sectors such as Rare Diseases an Orphan Drugs as well as how to invest into early stage projects and lead them to success in a capital efficient way.

“TVM Capital Life Science is a truly global Venture Capital firm dedicated to financing biopharmaceutical innovation in Canada, the USA and Europe. We are very proud to have invested in nine  innovative companies here in Quebec,  “, said Dr. Luc Marengere, Managing Partner, TVM Capital Life Science.

Dr. Nils Behnke, Director Bain & Company, highlighted the strong link between innovation, commercial success and category leadership in his talk. According to his research, the barriers holding biopharmaceuticals from becoming the leader in their segment are, amongst others, mostly internal barriers such as insufficient resources and a certain disability to focus.

Dr. Hubert Birner, Managing Partner, TVM Capital Life Science added: “We invest with the clear aim to make our investments the leader in their category. We not only provide necessary capital but the relevant networks to make these companies successful including our global faculty of research experts as well as very experienced industry managers.

“Historically, pharma research was done in-house but multinationals have realized that there is great research being done outside their walls,” says Vanessa Grant, a partner at Norton Rose Fulbright in Toronto. “The idea is to assist that research in the development stage so that companies can take a closer look at it later and provide additional value. Identifying promising research and leading it to a stage that is interesting for Big Pharma hold many opportunities for investors – provided the investors and their advisors have the necessary experience in this area.”

The TVM Capital Life Science Autumn Conference 2017 was sponsored by Norton Rose Fulbright, Aird & Berlis, Banque Nationale, Clark+Elbing, EY, Foley Hoag, Fonds de solidarité FTQ and RBC.

About TVM Capital Life Science

TVM Capital Life Science is providing venture capital to the international pharmaceutical, biopharmaceutical and medical technology industries with more than 30-years of transatlantic investment track record and more than US$1.4bn raised and under management. The TVM Capital Life Science international team looks back on more than 130 investments and over 90 exits, including more than 45 initial public offerings on all major U.S. and European stock exchanges and has gained unrivalled international investment experience with a long track record of dedicated board work, extensive global networks in the world of life science research and product development and a direct knowledge of the local markets. More information: www.tvm-lifescience.com

To view the agenda of the day, click here.

Media Contact:
Dr. Luc Marengere, Managing Partner, marengere@tvm-capital.com
Dr. Hubert Birner, Managing Partner, birner@tvm-capital.com
Monika Schlesinger, Marketing & Communications, schlesinger@tvm-capital.com